{"filing":{"accession_number":"0001104659-26-089008","cik":"0001821825","ticker":"OGN","company_name":"Organon \u0026 Co.","form":"8-K","filing_date":"2026-07-31","report_date":"2026-07-31","primary_document":"tm2621744d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1821825/000110465926089008/tm2621744d1_8k.htm"},"events":[{"id":22757,"run_id":20589,"accession_number":"0001104659-26-089008","anchor_item_number":"7.01","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"Organon disclosed its financial results for Q2 2026 (quarter ended June 30, 2026) via Form 10-Q filing on July 31, 2026, and furnished supplemental non-GAAP financial metrics in this Item 7.01 disclosure. Although the company suspended its customary earnings press release and conference call due to the pending Sun Pharmaceutical merger, the core disclosure—quarterly financial results with reconciled non-GAAP metrics (Adjusted EBITDA, Adjusted EPS, Adjusted Gross Margin, etc.)—constitutes an earnings release. The exhibit provides detailed reconciliations of GAAP to non-GAAP measures for both Q2 and six-month periods, which is material to investors assessing the company's financial performance.","company_name":"Organon \u0026 Co.","ticker":"OGN","filing_date":"2026-07-31","form":"8-K","submitted_at":null,"items":[{"id":22793,"accession_number":"0001104659-26-089008","item_number":"7.01","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Organon disclosed its financial results for Q2 2026 (quarter ended June 30, 2026) via Form 10-Q filing on July 31, 2026, and furnished supplemental non-GAAP financial metrics in this Item 7.01 disclosure. Although the company suspended its customary earnings press release and conference call due to the pending Sun Pharmaceutical merger, the core disclosure—quarterly financial results with reconciled non-GAAP metrics (Adjusted EBITDA, Adjusted EPS, Adjusted Gross Margin, etc.)—constitutes an earnings release. The exhibit provides detailed reconciliations of GAAP to non-GAAP measures for both Q2 and six-month periods, which is material to investors assessing the company's financial performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:23:20.126048+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":22793,"accession_number":"0001104659-26-089008","item_number":"7.01","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Organon disclosed its financial results for Q2 2026 (quarter ended June 30, 2026) via Form 10-Q filing on July 31, 2026, and furnished supplemental non-GAAP financial metrics in this Item 7.01 disclosure. Although the company suspended its customary earnings press release and conference call due to the pending Sun Pharmaceutical merger, the core disclosure—quarterly financial results with reconciled non-GAAP metrics (Adjusted EBITDA, Adjusted EPS, Adjusted Gross Margin, etc.)—constitutes an earnings release. The exhibit provides detailed reconciliations of GAAP to non-GAAP measures for both Q2 and six-month periods, which is material to investors assessing the company's financial performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:23:20.126048+00:00","company_name":"Organon \u0026 Co.","ticker":"OGN","filing_date":"2026-07-31"}]}